Evidence map›Paper›PMID 34272241›Full record

ArticleScience advances2021

Vitrification of octonary perylene mixtures with ultralow fragility.

Sandra Hultmark, Alex Cravcenco, Khushbu Kushwaha, Suman Mallick, Paul Erhart, Karl Börjesson, Christian Müller

Abstract read
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sandra HultmarkDepartment of Chemistry and Chemical Engineering, Chalmers University of Technology, 41296 Göteborg, Sweden.ORCID http://orcid.org/0000-0002-5289-4742
Alex CravcencoDepartment of Chemistry and Molecular Biology, University of Gothenburg, Kemigården 4, 41296 Göteborg, Sweden.ORCID http://orcid.org/0000-0001-7742-6139
Khushbu KushwahaDepartment of Chemistry and Molecular Biology, University of Gothenburg, Kemigården 4, 41296 Göteborg, Sweden.
Suman MallickDepartment of Chemistry and Molecular Biology, University of Gothenburg, Kemigården 4, 41296 Göteborg, Sweden.
Paul ErhartDepartment of Physics, Chalmers University of Technology, 41296 Göteborg, Sweden.ORCID http://orcid.org/0000-0002-2516-6061
Karl BörjessonDepartment of Chemistry and Molecular Biology, University of Gothenburg, Kemigården 4, 41296 Göteborg, Sweden.ORCID http://orcid.org/0000-0001-8533-201X
Christian MüllerDepartment of Chemistry and Chemical Engineering, Chalmers University of Technology, 41296 Göteborg, Sweden. christian.muller@chalmers.se.ORCID http://orcid.org/0000-0001-7859-7909

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strong glass formers with a low fragility are highly sought-after because of the technological importance of vitrification. In the case of organic molecules and polymers, the lowest fragility values have been reported for single-component materials. Here, we establish that mixing of organic molecules can result in a marked reduction in fragility. Individual bay-substituted perylene derivatives display a high fragility of more than 70. Instead, slowly cooled perylene mixtures with more than three components undergo a liquid-liquid transition and turn into a strong glass former. Octonary perylene mixtures display a fragility of 13 ± 2, which not only is a record low value for organic molecules but also lies below values reported for the strongest known inorganic glass formers. Our work opens an avenue for the design of ultrastrong organic glass formers, which can be anticipated to find use in pharmaceutical science and organic electronics.

Identifiers

PMID34272241
PMCPMC8284888

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.